NCT00974129

Brief Summary

The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2009

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

September 9, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 10, 2009

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2012

Completed
Last Updated

June 24, 2014

Status Verified

June 1, 2014

Enrollment Period

2.8 years

First QC Date

September 9, 2009

Last Update Submit

June 23, 2014

Conditions

Hemangioma

Study Arms (1)

Patients with Infantile Hemangiomas

Eligibility Criteria

AgeUp to 1 Year
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Patients to be recruited will include infants with hemangiomas on any part of their body.

You may qualify if:

  • Hemangioma must appear within one month prior to enrollment

You may not qualify if:

  • Hemangioma appeared before one month prior to enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yale Dermatology Associates

New Haven, Connecticut, 06519, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Over the course of the study, one blood draw will be performed on each patient. This blood will be used for genetic analysis.

MeSH Terms

Conditions

Hemangioma

Condition Hierarchy (Ancestors)

Neoplasms, Vascular TissueNeoplasms by Histologic TypeNeoplasms

Study Officials

  • Deepak Narayan, MD

    Yale University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 9, 2009

First Posted

September 10, 2009

Study Start

September 1, 2009

Primary Completion

June 1, 2012

Study Completion

June 1, 2012

Last Updated

June 24, 2014

Record last verified: 2014-06

Locations

US(1)